Published in final edited form as:

Science. 2013 July 19; 341(6143): 275–278. doi:10.1126/science.1233000.

Loss of Function of the Melanocortin 2 Receptor Accessory Protein 2 Is Associated with Mammalian Obesity

Masato Asai^{1,2}, Shwetha Ramachandrappa³, Maria Joachim¹, Yuan Shen¹, Rong Zhang¹, Nikhil Nuthalapati¹, Visali Ramanathan¹, David E. Storchlic¹, Peter Ferket⁴, Kirsten Linhart¹, Caroline Ho¹, Tatiana V. Novoselova⁵, Sumedha Garg³, Martin Ridderstråle⁶, Claude Marcus⁷, Joel N. Hirschhorn^{1,8}, Julia M. Keogh³, Stephen O'Rahilly³, Li F. Chan⁵, Adrian J. Clark⁵, I. Sadaf Farooqi^{3,*}, and Joseph A. Majzoub^{1,*}

¹Division of Endocrinology, Department of Medicine, Boston Children's Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115

²Departments of Pathology, Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan

³University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Institute of Metabolic Science, Addenbrooke's Hospital, CB2 0QQ, Cambridge, UK

⁴Prestage Department of Poultry Science, North Carolina State University, Raleigh, NC 27695

⁵William Harvey Research Institute, Centre for Endocrinology Queen Mary, University of London Barts and The London School of Medicine and Dentistry, London, EC1M 6BQ, UK

⁶Department of Clinical Sciences, Lund University, Malmö, Sweden and Steno Diabetes Center, Gentofte, Denmark

⁷Department for Clinical Science, Intervention and Technology, Karolinska Institute, Division of Pediatrics, National Childhood Obesity Centre, Stockholm, Sweden

⁸Department of Genetics, Harvard Medical School and Broad Institute, Cambridge, MA

Abstract

Melanocortin receptor accessory proteins (MRAPs) modulate signaling of melanocortin receptors *in vitro*. To investigate the physiological role of brain-expressed Melanocortin 2 Receptor Accessory Protein 2 (MRAP2), we characterized mice with whole body and brain-specific targeted deletion of *Mrap2*, both of which develop severe obesity at a young age. *Mrap2* interacts directly with Melanocortin 4 Receptor (Mc4r), a protein previously implicated in mammalian obesity, and it enhances Mc4r-mediated generation of the second messenger cyclic AMP, suggesting that alterations in Mc4r signaling may be one mechanism underlying the association between *Mrap2* disruption and obesity. In a study of humans with severe, early-onset obesity, we found four rare, potentially pathogenic genetic variants in *MRAP2*, suggesting that the gene may also contribute to body weight regulation in humans.

*Correspondence to: Joseph A. Majzoub, joseph.majzoub@childrens.harvard.edu, I. Sadaf Farooqi, isf20@cam.ac.uk.

Supplementary Online Materials

www.sciencemag.org

Materials and Methods

Figs. S1, S2, S3, S4

Tables S1, S2, S3

References (13–18) [Note: The numbers refer to additional references cited only within the Supplementary Online Materials]

Author Contributions

Membrane-expressed G protein-coupled receptors (GPCRs) modulate cellular responses to numerous physiological stimuli. The melanocortin receptors (MCRs) are a subfamily of GPCRs that mediate signaling in response to the pro-opiomelanocortin-derived peptides, adrenocorticotrophic hormone (ACTH) and α -melanocyte-stimulating hormone (α -MSH) and their competitive antagonists, agouti and agouti-related protein. The MCRs mediate a diverse range of physiological functions: MC1R is involved in skin pigmentation, MC2R plays a critical role in the hypothalamic-pituitary-adrenal axis, MC3R and MC4R are involved in energy homeostasis and MC5R is implicated in exocrine function (1).

There is increasing recognition that accessory proteins can modulate GPCR trafficking, as well as ligand binding and signaling (2). An accessory protein for MC2R, MC2R accessory protein (MRAP), is required for the trafficking of MC2R to the surface of adrenal cells and for signaling in response to ACTH (3, 4). Loss of either MC2R or MRAP in humans causes severe resistance to ACTH, with resulting glucocorticoid deficiency (5, 6).

All mammals have a paralogous gene, *MRAP2*, which, like *MC3R* and *MC4R*, is predominantly expressed in the brain (7), most prominently in the pons and cerebellum, but including in regions involved in energy homeostasis such as the hypothalamus and brainstem (Fig. S1, A–C). Within the paraventricular nucleus of the hypothalamus (PVN), *Mrap2* and *Mc4r* mRNAs are co-expressed in many cells (Fig. S1D). We hypothesized that *Mrap2* might modulate signaling through a melanocortin receptor and potentially affect energy homeostasis. We therefore performed targeted deletion of *Mrap2* in mice, using Cre-lox-mediated excision of the 100 bp exon 3 (which encodes the highly conserved transmembrane domain (7)) to create mice with normal levels of an mRNA predicted to encode a truncated protein that includes the first 55 amino acids of *Mrap2*, with the transmembrane domain replaced by 11 aberrant amino acids specified by the out-of-frame exon 4, followed by a stop codon (Fig. S1, E–H). Normal levels of the mutant mRNA indicate preservation of *Mrap2*-containing neurons in null mice, although these neurons likely do not express the predicted mutant protein, since mutant *Mrap2* mRNA, but not protein, is present in cells transfected with the same *Mrap2* mutant construct used to create the null mice (Fig. S1I).

Mrap2 null mice appeared normal at birth, with normal weight gain and post-weaning food intake during early life (0–32 days and 23–32 days, respectively), although young *Mrap2*^{−/−} male mice trended toward greater weight and food intake with advancing age (Fig. S1J). However, null mice of both genders gradually became extremely obese on a diet of regular chow *ad libitum* (Fig. 1A, S2A). Heterozygous mice were significantly heavier than wild-type animals on standard chow (160–175 days; males, *Mrap2*^{+/+} 26.0±0.4 g, *Mrap2*^{+/-} 29.9±0.9 g; females *Mrap2*^{+/+} 24.5±0.9 g, *Mrap2*^{+/-} 28.1±0.7 g), and at younger ages (56–95 days) on a high fat diet (Fig. 1A). In addition, *Mrap2*^{−/−} mice had increased length (Fig. S1K) and per cent of weight due to fat, and decreased per cent of weight due to lean mass (Fig. S1L). Both genders of *Mrap2*^{−/−} mice had increased visceral adiposity, over twice the normal white adipose tissue cell size, enlarged brown adipose tissue depots, normal liver histology on a regular chow diet, but much greater hepatic steatosis compared with wild-type mice on a high fat diet (Fig. 1B, Fig. S2, A–B). Adult *Mrap2* null mice had, as expected, elevated leptin concentrations corresponding to their increased fat mass, which normalized with diet-induced weight normalization (Fig. S2C). Obese adult mice had normal fasting insulin (Fig. S2D) and normal tolerance to intraperitoneal glucose injection (Fig. S2E). *Mrap2* has been postulated to play a role in the adrenal response to ACTH (8). We therefore measured diurnal rhythmicity and stress responsiveness of the adrenal axis in *Mrap2* null mice, which were normal (Fig. S2F). Thyroid hormone levels were also normal (Table S1). Epinephrine and norepinephrine excretion were reduced in male *Mrap2*^{−/−} mice

only (Fig. S2G), but *Ucp1* mRNA concentrations increased appropriately in both genders of null mice following exposure to 4°C for 18h (Fig. S2H). Hypothalamic *Agrp* mRNA concentration was reduced in *Mrap2* null mice, whereas *Pomc* mRNA was normal (Fig. S2I).

To characterize the mechanisms underlying the obesity in these mice, we measured food intake under a variety of conditions. At 42 (Fig. S2J) and 84 (Fig. S2K) days of age, when *Mrap2*^{-/-} mice were clearly overweight, no difference in food intake was detected between the two genotypes when analyzed over a 4-day interval. Obesity was not caused by more efficient absorption of calories in null mice (Fig. S2L). Only when monitored daily over 50 days (ages 34–84 days) was a subtle increase in cumulative food intake discernable in the null animals (Fig. 2A), with the onset of obesity preceding hyperphagia (Fig. 2A and Fig. S2M). To further understand the contribution of hyperphagia to obesity in *Mrap2*^{-/-} mice, we limited their food intake to that amount consumed by their normal siblings (pair feeding). Even when fed the same amount of chow, null mice gained more weight than did wild-type mice (Fig. S2N and Fig. S2O). Only when the amount of food intake in null mice was further restricted to 10% (females) and 13% (males) less than that of wild-type mice was there equivalent weight gain (Fig. S2P) in the two genotypes. To determine whether the late onset hyperphagia in *Mrap2*^{-/-} mice (Fig. 2A) could simply be the consequence of an increased body mass at this older age caused by a separate metabolic defect, we switched null mice to *ad libitum* access to chow after 40 days of restricted feeding (upward arrow, Fig. S2P). During the first 24 h of *ad libitum* feeding, food intake almost doubled in null mice (from 2.9±0.1 to 5.6±0.5 g/d in males, and from 2.8±0.1 to 5.3±0.2 g/d in females), with a corresponding marked increase in body weight. Thus, hyperphagia develops in an age-dependent manner in older mice, independent of body weight. Consistent with this, young (age 38–45 days) *Mrap2*^{-/-} mice had an intact anorectic response to the melanocortin receptor (Mc4r and Mc3r) agonist, MTII (Fig. S2Q), corresponding to their normal *ad libitum* food intake at this age.

We hypothesized that young *Mrap2*^{-/-} mice might display abnormal energy expenditure because obesity develops early during *ad libitum* feeding prior to the onset of hyperphagia, persists in mutant mice pair-fed to a normal dietary intake, and is abolished only by underfeeding. To explore this, we measured energy expenditure and respiratory exchange ratio (RER) by indirect calorimetry, as well as locomotor activity and core body temperature, in young (30–45 days of age) wild-type and *Mrap2* null mice, just as their weights began to diverge (Fig. 2A). Surprisingly, the wild-type and mutant mice had indistinguishable 24h total energy expenditure, as analyzed by ANCOVA (9) (Fig. 2B). There were also no differences between *Mrap2*^{+/+} and *Mrap2*^{-/-} mice in RER (Fig. S2R), locomotor activity (Fig. S2S), or core body temperature at 22°C (Fig. S2T), with both genotypes exhibiting the expected increase in all three parameters during the active night period. Following exposure to 4°C for 18h, null and wild-type mice became significantly hypothermic to the same extent (Fig. S2T).

Since 1) MRAP is essential for signalling through MC2R (3, 4), 2) MRAP's paralog, *Mrap2*, is expressed principally in the brain, and 3) Mc2r's paralog, Mc4r, has a key role in energy balance in *Sim1*-containing neurons (10), we asked whether deletion of *Mrap2* causes obesity in part by altering signaling through centrally-expressed Mc4r. We created a *Sim1*^{Cre::Mrap2}^{fllox/fllox} mouse with conditional deletion of *Mrap2* exclusively in these neurons, and expression of *Mrap2*^{Del} mRNA only in hypothalamus and not cerebral cortex or brainstem (Figs. S3A, 3A). Like global null mice, conditional mutants were similarly obese (Fig. 3B), and pair-feeding to a normal dietary intake only partially reversed their obesity (Fig. S3B).

If *Mrap2* facilitates the action of *Mc4r*, then *Mc4r* deficiency should create an equivalent or more severe obesity phenotype than does *Mrap2* deficiency, depending on the degree to which *Mrap2* interferes with *Mc4r* function. Supporting this, *Mrap2*^{+/-} mice of both genders were less obese than either *Mc4r*^{+/-} or doubly heterozygous mice (Fig. S3C). The differences between *Mc4r*^{+/-} and doubly heterozygous mice were not statistically significant, although the latter trended toward being heavier. Among homozygous knockouts, those with *Mc4r* deficiency alone were more obese than those with *Mrap2* deficiency alone (Fig. S3C). The *Mc4r* knockout mice were more obese than mice with deletion of both *Mc4r* and *Mrap2* (in males, with a trend in females), suggesting that *Mrap2* may promote weight gain through both *Mc4r*-dependent and *Mc4r*-independent actions.

To determine whether mouse *Mrap2* and *Mc4r* can interact directly, we co-immunoprecipitated transiently expressed, N-terminally Myc-tagged *Mrap2* and N-terminally GFP-tagged *Mc4r* in CHO cells (devoid of endogenous *Mrap*, *Mrap2* and melanocortin receptors). We found that mouse *Mrap2* and *Mc4r* interact (Fig. S3D), consistent with previous data (7). We next investigated the impact of *Mrap2* on *Mc4r* (Fig. 3C) and *Mc3r* (Fig. S3E) signaling. The combined expression of *Mc4r* and *Mrap2* in CHO cells suppressed basal PKA signaling compared with *Mc4r* alone (Fig. 3C, left panel), as previously reported with the human orthologs (7). But in contrast to that report (which used NDP-MSH), we found that MSH caused a 5-fold increase above basal PKA activity (Fig. 3C, right panel) compared with less than a 2-fold increase with *Mc4r* alone or *Mc4r* plus the *Mrap2* null construct, *Mrap2*^{delE3} (our *in vitro* model for *in vivo* disruption of *Mrap2*). The presence of *Mrap2* increased signaling through *Mc3r* at the two highest MSH doses (Fig. S3D). These findings suggest *Mrap2* may alter signalling through *Mc4r* and perhaps other receptors.

To investigate whether alterations in *MRAP2* are associated with human obesity, we sequenced the coding region and intron/exon boundaries of *MRAP2* in obese and control individuals from the Genetics of Obesity Study (GOOS) cohort (11) and the Swedish obese children's cohort (12). Four rare heterozygous variants were found in unrelated, nonsyndromic, severely obese individuals, that were absent from cohort-specific controls and 1000 genomes (Table), with all but one in the C-terminal region of the protein (Fig. S4). In three of these subjects, no pathogenic variants were found in the coding region or intron/exon boundaries of all known nonsyndromic human obesity genes (Table S2). Only one of the variants (E24X) is clearly disruptive, and overall few rare variants were found in the obese cohorts, indicating that *MRAP2* mutations, if they contribute to severe human obesity, do so rarely.

In summary, we have found that global or brain-specific inactivation of *Mrap2* causes obesity in mice and that rare heterozygous variants in *MRAP2* are associated with early-onset, severe obesity in humans. The mechanism(s) by which *Mrap2* exerts its effects on body weight regulation remain to be firmly established but likely involve altered signaling through *Mc4r* and perhaps other melanocortin receptors. Under conditions comparable to those we describe whereby *Mrap2* greatly enhances cAMP signaling through *Mc4r*, Sebag et al. (*new reference*) have found that the zebrafish ortholog of *Mrap2* (*zMRAP2b*) similarly affects *zMC4R* signaling. This evolutionary conservation, plus the extreme disease phenotype caused by loss of *Mrap2* function, supports the importance of *Mrap2* in vertebrate biology.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank T. Nguyen for DNA analysis, H. Feldman and A. Fleisch for statistical advice; M. Mulcahey for thyroid assays, H. Turkova for catecholamine assays, S. Cabi for creating the software program used to analyze calorimetry data, M. Geibel for bioinformatics analyses, and D. Margulies, B. Lowell, J. Flier, and Boston Children's Hospital Endocrinology Division scientists for helpful discussions. We are indebted to the patients and their families for their participation and to the physicians involved in the Genetics of Obesity Study (GOOS) and the Swedish obese children's cohort study. This work was supported by grants from the National Institutes of Health (J.A.M.), the Timothy Murphy Fund (J.A.M.), NARSAD (M.A.), the Wellcome Trust (I.S.F., S.O'R.), Medical Research Council (I.S.F., L.F.C. [grant number G0802796]), NIHR Cambridge Biomedical Research Centre (I.S.F., S.O'R.), and R01DK075787 (J.N.H.). S.O'R. is a paid Scientific Advisor for Pfizer, Inc. in the area of cardiometabolic disease. Until 2010, J.A.M. was on the Board of, and was a paid Scientific Advisor for, Correlagen Diagnostics, Inc., a company whose projects included molecular diagnostic tests related to obesity.

References and Notes

1. Cone RD. Studies on the physiological functions of the melanocortin system. *Endocrine reviews*. Dec.2006 27:736. [PubMed: 17077189]
2. Hay DL, Poyner DR, Sexton PM. GPCR modulation by RAMPs. *Pharmacology & therapeutics*. Jan. 2006 109:173. [PubMed: 16111761]
3. Hinkle PM, Sebg JA. Structure and function of the melanocortin2 receptor accessory protein (MRAP). *Molecular and cellular endocrinology*. Mar 5.2009 300:25. [PubMed: 19028547]
4. Cooray SN, Clark AJ. Melanocortin receptors and their accessory proteins. *Molecular and cellular endocrinology*. Jan 15.2011 331:215. [PubMed: 20654690]
5. Metherell LA, et al. Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2. *Nature genetics*. Feb.2005 37:166. [PubMed: 15654338]
6. Chan LF, Metherell LA, Clark AJ. Effects of melanocortins on adrenal gland physiology. *Eur J Pharmacol*. Jun 11.2011 660:171. [PubMed: 21211533]
7. Chan LF, et al. MRAP and MRAP2 are bidirectional regulators of the melanocortin receptor family. *Proc Natl Acad Sci U S A*. Apr 14.2009 106:6146. [PubMed: 19329486]
8. Sebg JA, Hinkle PM. Regulation of G protein-coupled receptor signaling: specific dominant-negative effects of melanocortin 2 receptor accessory protein 2. *Science signaling*. 2010; 3:ra28. [PubMed: 20371771]
9. Tschoep MH, et al. A guide to analysis of mouse energy metabolism. *Nature methods*. Jan.2012 9:57. [PubMed: 22205519]
10. Balthasar N, et al. Divergence of melanocortin pathways in the control of food intake and energy expenditure. *Cell*. Nov 4.2005 123:493. [PubMed: 16269339]
11. Farooqi S, O'Rahilly S. Genetics of obesity in humans. *Endocrine reviews*. Dec.2006 27:710. [PubMed: 17122358]
12. Johansson LE, et al. Genetic variance in the adiponutrin gene family and childhood obesity. *PLoS One*. 2009; 4:e5327. [PubMed: 19390624]
13. Altarejos JY, et al. The Creb1 coactivator Crtc1 is required for energy balance and fertility. *Nature medicine*. Oct.2008 14:1112.
14. Halley JT, Nelson TS, Kirby LK, Johnson ZB. Relationship between dry matter digestion and metabolizable energy. *Poultry science*. Oct.1985 64:1934.
15. Adams DJ, et al. A genome-wide, end-sequenced 129Sv BAC library resource for targeting vector construction. *Genomics*. Dec.2005 86:753. [PubMed: 16257172]
16. Liu P, Jenkins NA, Copeland NG. A highly efficient recombineering-based method for generating conditional knockout mutations. *Genome research*. Mar.2003 13:476. [PubMed: 12618378]
17. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. *Nature protocols*. 2008; 3:1101.
18. Liu H, et al. Transgenic mice expressing green fluorescent protein under the control of the melanocortin-4 receptor promoter. *J Neurosci*. Aug 6.2003 23:7143. [PubMed: 12904474]

Fig. 1.

Phenotype of *Mrap2*^{-/-} mice. (A) Weight curves for *Mrap2*^{+/+} vs. *Mrap2*^{+/-} vs. *Mrap2*^{-/-} mice on standard chow (Chow, upper panels: male n= 9 vs. 28 vs. 15, female n=12 vs. 18 vs. 10) or high fat diets (HFD, ages 56–95 days, lower panels, superimposed on standard chow curves: male n= 10 vs. 8 vs. 10, female n=7 vs. 12 vs. 7). For both genders the weight curves of *Mrap2*^{+/+} and *Mrap2*^{+/-} mice on standard chow differ significantly at older (161–175 days) ages, and at younger ages (56–95 days) on a high fat diet. *. *p*≤.02, ***p*≤.001, ****p*≤.0003. (B) Fat depots on standard chow diet. Upper panel: White adipose tissue (WAT) weights in *Mrap2*^{+/+} vs. *Mrap2*^{-/-} (males and females, ages 117–122 days, n=5 vs. 4, respectively). Lower left panel: BAT weight in *Mrap2*^{+/+} vs. *Mrap2*^{-/-} mice (males and females, ages 117–122 days, n=5 vs. 4). Lower right panel: WAT cell size in *Mrap2*^{+/+} vs. *Mrap2*^{-/-} mice (females, 50 cells counted from each mouse). **p*≤.009, ***p*≤.003, ****p*≤.0003, *****p*≤.00001.

Fig. 2.

Energy balance in *Mrap2*^{-/-} mice. (A) Cumulative food intake (upper panels) and weight (lower panels) in *ad libitum* fed *Mrap*^{+/+} vs. *Mrap2*^{-/-} males (n=10 vs. 11) and females (n=11 vs. 8). (B) Energy expenditure in *ad libitum*-fed *Mrap*^{+/+} vs. *Mrap2*^{-/-} mice. Upper panels, continuous measurement over 3 days, males (n=3 vs. 4), females (n=4 vs. 3), ages 30–34 days. Lower panels: body weight vs. energy expenditure, integrated over 24 h, males (n=18 vs. 14, ages 30–45 days), females (n=16 vs. 11, ages 30–42 days). Analysis by ANCOVA showed no differences between genotypes (males, p=.38, females, p=.67).

Fig. 3.

Interaction between *Mrap2* and *Mc4r*. (A) Conditional deletion of *Mrap2* in *Sim1* neurons. Top right, Cre DNA analysis by PCR. HT DNA from *Sim1^{CreBAC::Mrap2^{fl/f}}* mice contains *Cre* (374 bp), but from *Mrap2^{fl/f}* mice does not. Molecular weight marker (M) on right (bp). Top left, *Mrap2* DNA analysis in *Sim1^{CreBAC::Mrap2^{fl/f}}* and *Mrap2^{fl/f}* mice by PCR. Both genotypes contain floxed, intact *Mrap2* DNA in CX, HT, and BS (314 bp in upper electropherogram, and 1013 bp in lower electropherogram, molecular weight markers on left). Only *Sim1^{CreBAC::Mrap2^{fl/f}}* mice contain *Mrap2^{Del}* (400 bp, lower electropherogram), and only in HT and BS, but not in CX, consistent with fluorescent reporter data (Fig. S3A). No PCR products are present without added DNA (H2O). Bottom, *Mrap2* mRNA expression in *Sim1^{CreBAC::Mrap2^{fl/f}}* and *Mrap2^{fl/f}* mice by RT-PCR. Both genotypes express floxed, intact *Mrap2* mRNA in CX, HT, and BS (247 bp). Only *Sim1^{CreBAC::Mrap2^{fl/f}}* mice express *Mrap2^{Del}* mRNA (147 bp), and only in HT. Global *Mrap2^{Del/Del}* mice express *Mrap2^{Del}* mRNA in all 3 sites. (B) Body weights of *Mrap2^{+/+}* (male n=6, female n=11), *Mrap2^{-/-}* (male n=11, female n=7), *Mrap2^{fl/f}* (male n=8, female n=12) and conditional *Sim1^{CreBAC::Mrap2^{fl/f}}* mice (male n=8, female n=7) mice, all age 133 days. *p=.04, **p=.007, ***p=.0002, ****p<.0001. (C) Effect of *Mrap2* on *Mc4r* signaling. Left panel: Level of cAMP reporter activity (CRELuc) in CHO cells alone, or co-transfected with *Mc4r*, with or without *Mrap2* or the *Mrap2* knockout construct, *Mrap2delE3*, 5 h following exposure to 0–10 nM MSH (n=3/group). Right panel: cAMP activity of these same constructs, expressed as percent induction following 0–10 nM MSH, relative to 0 nM MSH. *p<.0001, *Mc4r* +*Mrap2* vs. *Mc4r* at same [MSH], by ANOVA. For most data points, error bars are obscured by symbols.

Table

MRAP2 variants detected in obese subjects and controls

MRAP2 variant	Subjects with variant	* Subject Sex/Age/BMI/BMI SDS	Controls with variant	** MAF: European American	** MAF: African American	*** Polyphen prediction
E24X	1/488	M/19/63/4.7	0/488	0.000% (0/8600)	0.000% (0/4406)	damaging
N88Y	1/376	M/11/29.6/3.3	0/376	0.000% (0/8600)	0.000% (0/4406)	possibly damaging
L115V	1/488	M/5/24/4.2	0/488	0.012% (1/8600)	0.000% (0/4406)	benign
R125C	1/488	F/8/29/3.5	0/488	0.047% (4/8600)	0.045% (2/4406)	possibly damaging

* Subject Sex (Male[M], Female[F])/Age (y)/BMI (kg/m²)/SDS (standard deviation score)

** MAF (minor allele frequency, NHLBI exome variant server <http://evs.gs.washington.edu/EVS/>)

*** Polyphen (<http://genetics.bwh.harvard.edu/pph2/>)